Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Adults ≥ 18 years
Prediabetes (FPG 100-125 mg/dL or HbA1c 42-47 mmol/mol), or Type 1 or Type 2 diabetes
Elevated cholesterol or triglycerides (TC ≥200 mg/dL, LDL 130-189 mg/dL, or TG \>150 mg/dL)
Either no lipid-lowering medication or stable dose for ≥4 weeks
Able to swallow capsules and understand Danish
Willing to maintain lifestyle habits and provide stool and blood samples

Antibiotic use in the past 3 months
Severe dyslipidemia (\>500 mg/dL triglycerides)
Significant liver, kidney, thyroid disease
Pregnancy or breastfeeding
GI surgery or chronic GI disease (IBD, IBS, Crohn's disease)
Long-term medications influencing lipid/glucose metabolism (except approved antidiabetic medications)
Participation in another trial within 3 months
Capsule intake \<80%

Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus